- Home
- CSTL
as 12-24-2024 4:00pm EST
Castle Biosciences Inc is a commercial-stage dermatological cancer company. It is focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The product portfolio of the company includes Cutaneous Melanoma, DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME among others.
| Founded: | 2007 | Country: | United States |
| Employees: | N/A | City: | FRIENDSWOOD |
| Market Cap: | 848.1M | IPO Year: | 2019 |
| Target Price: | $39.67 | AVG Volume (30 days): | 301.1K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.21 | EPS Growth: | N/A |
| 52 Week Low/High: | $16.97 - $35.84 | Next Earning Date: | 11-04-2024 |
| Revenue: | $311,878,000 | Revenue Growth: | 62.43% |
| Revenue Growth (this year): | 51.36% | Revenue Growth (next year): | -18.55% |
Stock Insider Trading Activity of Castle Biosciences Inc. (CSTL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Dec 17 '24 | Sell | $28.55 | 9,364 | $265,357.92 | 84,874 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Dec 13 '24 | Sell | $28.82 | 26,123 | $750,296.13 | 84,874 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Dec 5 '24 | Sell | $31.35 | 5,127 | $160,741.70 | 84,874 | |
| BRADBURY DANIEL | CSTL | Director | Dec 3 '24 | Sell | $31.14 | 7,867 | $243,692.99 | 10,382 | |
| Stokes Frank | CSTL | Chief Financial Officer | Nov 15 '24 | Sell | $30.14 | 6,923 | $207,217.21 | 31,623 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Nov 12 '24 | Sell | $34.15 | 5,127 | $175,087.05 | 84,874 | |
| Juvenal Tobin W | CSTL | Chief Commercial Officer | Nov 5 '24 | Sell | $35.56 | 3,507 | $124,708.92 | 54,178 | |
| MAETZOLD DEREK J | CSTL | Pres. & Chief Exec. Officer | Nov 4 '24 | Sell | $32.84 | 5,127 | $166,819.96 | 84,874 | |
| BRADBURY DANIEL | CSTL | Director | Nov 1 '24 | Sell | $34.72 | 7,867 | $273,251.23 | 10,382 | |
| Juvenal Tobin W | CSTL | Chief Commercial Officer | Nov 1 '24 | Sell | $35.39 | 3,100 | $109,709.00 | 54,178 |
Latest Castle Biosciences Inc. News
CSTL Breaking Stock News: Dive into CSTL Ticker-Specific Updates for Smart Investing
Medical Device Network
2 days ago
Castle Biosciences reports preliminary data from atopic dermatitis test study
Zacks
3 days ago
Vertex Secures FDA Approval for New Cystic Fibrosis Drug Alyftrek
Business Wire
3 days ago
Castle Biosciences Highlights Progress for its Pipeline Atopic Dermatitis Gene Expression Profile Test
Zacks
7 days ago
KRYS Reports Upbeat Initial Data From Lung Cancer Study of KB707
Zacks
7 days ago
SRPT Finishes Enrolment in Late-Stage Study for Rare Muscular Disorder
Business Wire
7 days ago
Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Zacks
9 days ago
Merck Ends Development of Two Experimental Cancer Drugs
Zacks
9 days ago
4 Solid Net Profit Margin Stocks to Boost Portfolio Returns
Compare CSTL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CSTL Castle Biosciences Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.